Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs(®)) lenalidomide (LEN) and pomalidomide (POM) play a central role in combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Thakurta, Anjan, Pierceall, William E., Amatangelo, Michael D., Flynt, Erin, Agarwal, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310669/
https://www.ncbi.nlm.nih.gov/pubmed/34316334
http://dx.doi.org/10.18632/oncotarget.27973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310669/
https://www.ncbi.nlm.nih.gov/pubmed/34316334
http://dx.doi.org/10.18632/oncotarget.27973

Ejemplares similares